| Source: HalifaxProj(inhibit) |
| Type: |
| NF-kB signaling Nuclear factor kappa B (NF-κB) is a transcription factor that plays a crucial role in regulating immune response, inflammation, cell proliferation, and survival. NF-κB is often found to be constitutively active in many types of cancer cells. This persistent activation can promote tumorigenesis by enhancing cell survival, proliferation, and metastasis. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 1564- | Api, | Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 581- | Api, | Cisplatin, | The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy |
| - | in-vitro, | Pca, | CD44+ |
| 211- | Api, | Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice |
| - | in-vivo, | Pca, | NA |
| 240- | Api, | The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | CD44+ |
| 237- | Api, | Apigenin blocks IKKα activation and suppresses prostate cancer progression |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | 22Rv1 | - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | DU145 |
| 147- | ATG, | EGCG, | CUR, | Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | MCF-7 |
| 5828- | CAP, | Capsaicin: a novel radio-sensitizing agent for prostate cancer |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2013- | CAP, | Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vivo, | NA, | NA |
| 5761- | CAPE, | Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of AMPK and Akt signaling networks |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5951- | Cela, | Celastrol Suppresses Tumor Cell Growth through Targeting an AR-ERG-NF-κB Pathway in TMPRSS2/ERG Fusion Gene Expressing Prostate Cancer |
| - | vitro+vivo, | Pca, | NA |
| 136- | CUR, | docx, | Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 161- | CUR, | MeSA, | Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 |
| 123- | CUR, | Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells |
| - | in-vitro, | Colon, | LoVo | - | in-vitro, | Colon, | COLO205 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 124- | CUR, | Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 158- | CUR, | Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 164- | CUR, | Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro |
| - | in-vitro, | Pca, | PC3 |
| 160- | CUR, | Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2 |
| - | in-vitro, | Pca, | NA |
| 170- | CUR, | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| - | vitro+vivo, | Pca, | PC3 |
| 182- | CUR, | RES, | GI, | Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 183- | CUR, | Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 26- | EGCG, | QC, | docx, | Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy |
| - | vitro+vivo, | Pca, | PC3 |
| 825- | GAR, | Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | Bxpc-3 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 1644- | HCAs, | PBG, | Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 1667- | PBG, | Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 5185- | PEITC, | SFN, | Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
| 1985- | PTL, | KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PrEC | - | in-vivo, | NA, | NA |
| 61- | QC, | Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | ARPE-19 |
| 85- | QC, | Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 3369- | QC, | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
| - | Review, | Pca, | NA |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 5112- | SSE, | https://pubmed.ncbi.nlm.nih.gov/19811770/ |
| - | in-vitro, | Pca, | PC3 |
| 139- | Tomatine, | CUR, | Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:214 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid